Mission:

FUNDING CANCER RESEARCH TO FIND A CURE


 http://www.cancerresearchfdn.org
 |  3354 N PAULINA ST STE 208 CHICAGO IL 60657-1087

CANCER RESEARCH FOUNDATION is headquartered in CHICAGO, IL, has an EIN of 81-2771469, and is a 501(c)(3) organization. Donations may or may not be tax-deductible.  It is classified by the IRS as a Charitable Organization, with a ruling year of 2017.

(Source: IRS Business Master File and Form 990)


...  ...  ...  ...  

Encompass Rating System by Charity Navigator


Charity Navigator’s Encompass Rating System evolves on a quarterly basis as we add new measures and indicators, which we call Beacons. Check back often to see how this organization’s score changes.

Learn about the Encompass Rating System: Announcement | FAQ | Release Notes


Charity Navigator provides 501(c)(3) nonprofits with an Encompass Rating when we have available data. Please see the sections below for more information on why this organization is not currently rated.

This organization cannot be evaluated by our Encompass Rating methodology due to only having 2 years of data

To ensure year-to-year consistency the Encompass Rating System’s Finance & Accountability beacon analyzes the three-year average of some data provided through the IRS 990.
Charity Navigator currently only has 2 years of consecutive e-filed Forms 990 from the IRS for CANCER RESEARCH FOUNDATION under the EIN: 81-2771469.
Before Charity Navigator can evaluate this organization, CANCER RESEARCH FOUNDATION will need to e-file for additional fiscal years.


Looking for this charity in our old design?

Back to Top

...   Finance & Accountability


Charity Navigator evaluates a nonprofit organization’s financial health including measures of stability, efficiency and sustainability. We also track accountability and transparency policies to ensure the good governance and integrity of the organization.


This organization is ineligible for a Finance & Accountability score. Find out why.

...   Impact & Results


Charity Navigator will evaluate available data on the results that a nonprofit organization achieves towards delivering on its stated mission. There are many ways to assess such impact and we intend to experiment and develop leveraging various methodologies.


Impact & Results Score (BETA)

Coming Soon

Encompass Rating Beta V1 does not provide an evaluation of the organization's program impact and the results of its work. If a nonprofit organization submitted their self-report impact data to any of our partners it will be displayed below.



Impact & Results Rating Highlights

This organization's programs include:

Amount Spent
% of Program Expense
Program Description

$75,000

45%

GRANTS TO SCIENTISTS AT UNIVERSITY MEDICAL CENTERS FOR CLINICAL AND LABORATORY RESEARCH ON VARIOUS PROJECTS

$71,873

43%

PAYROLL AND PAYROLL TAXES

$17,183

10%

RELATED EXPENSES INCURRED LISTED IN III 4A LESS PAYROLL EXPENSES

Back to Top

Impact & Results Report

(Score Coming Soon)


This beta feature is currently viewable only on desktop or tablet screens. Check back later for updates.

Overview

Overview


Impact & Results data is available for this charity from one or more of our data partner organizations.

Impact & Results scores are not available in Encompass Rating System Beta V1.

GuideStar Gold Seal of Transparency

GuideStar is Charity Navigator's trusted partner in sharing information on how this organization seeks impact. GuideStar has recognized this organization with a Gold Seal of Transparency for voluntarily and publicly describing their goals, strategies, and accomplishments. Click here for more information.

Note: Encompass Rating Beta V1 does not incorporate impact data into a charity's rating.


What is your organization aiming to accomplish?

More than 70 years ago, our founder, Maurice Goldblatt, asked himself “What would the world look like if cancer were no longer the disease it is today?” To answer that question, the Cancer Research Foundations strives to create the greatest possible opportunities for major breakthroughs in cancer science by leveraging money where financial support is needed most – and doing it in the most efficient way possible. One way we do this is by young investigators, early career cancer scientists who face a real danger of not finding funding for primary data sets. Often one of the most difficult points in a young researcher’s career, if a young investigator does not find funding, he or she might never get the chance to make the next great breakthrough in cancer science. Our goal is to bridge that gap, an support young scientists when funding is difficult.


What are your strategies for making this happen?

The Cancer Research Foundation is dedicated to supporting innovation in cancer science and backing the application of new minds and original ideas to discover novel and more efficient ways to prevent, treat and cure cancer. For more than 70 years, the Cancer Research Foundation has been instrumental in supporting research and science leading to important discoveries that have reduced suffering and extended life. Our strategy is to provide funding to scientists much in the same was a venture capitalist provides seed money to a new and exciting idea or entrepreneur, making early stage grants that are focused on novel ideas and new technologies which may be still too risky for more traditional science funders. The most important goal of the Chicago Chapter is to allow the CRF to grow the Young Investigator Award, our most important grant-making vehicle. The Young Investigator Award was formally established more than 25 years ago to support young cancer researchers.


What are your organization's capabilities for doing this?

Throughout our history, the Cancer Research Foundation’s grants have been guided by the desire to fund “tomorrow’s big discoveries” in cancer. We support researchers studying cancer, young scientists searching for new directions, and senior scientists poised on the brink of new discovery. Our greatest capability springs from our history and our track record in funding cancer. Not only have we supported early career scientists who have gone on to become leaders in cancer research, we maintain relationships with our past grantees and they help inform our funding decisions. We also maintain strong connections with the National Cancer Institute recognized Comprehensive Cancer Centers at which we have funded more than 180 scientists. Additionally, we are not restricted to only one type of cancer or one field of science, which allow us to help new technologies and novel ideas enter cancer science, from fields like data science, molecular engineering and biochemistry.


How will your organization know if you are making progress?

Today, after more than seventy years , we are starting to see real promise of a world in which cancer is thought of as a chronic disease rather than a deadly one. Recent investigation has revealed new similarities in the way cancers are constructed and propagate and major advances have been made in pinpointing the mechanics of metastasis and identifying why one person develops cancer when another does not. We can start to see a future in which a diagnosis of cancer is most often tempered by a discussion of how to manage the disease, just as you might manage high blood pressure or diabetes. These are clear indicators of real change in the way we battle cancer, but they are not enough.


What have and haven't you accomplished so far?

We are proud to have been involved in major discoveries in scientific fields as varied as early imaging and personalized proteomics. The CRF was an early supporter of Dr. Janet Rowley, who discovered the first consistent chromosome translocations in human cancer and showed the world that cancer could be a genetic disease. Today, Cancer Research Foundation funded scientists are focused on identifying the particular mutations that lead to genetic cancer predisposition This just one of many instances where the CRF funding has supported the arc of cancer knowledge at multiple points. From the beginning, the CRF has supported ground breaking cancer science by funding scientists who might otherwise be caught in the “catch 22” of having a new idea but no support to fund the data required to secure funding. The landscape of cancer treatment, prevention and cure has changed radically since we started funding cancer science and our support has been important in many of those changes.



ImpactMatters Data


We display the ImpactMatters ratings on particular programs of nonprofit organizations. Click here for more information about ImpactMatters ratings.

Note: Encompass Rating Beta V1 does not incorporate impact data into a charity's rating.


GlobalGiving


GlobalGiving is the largest global crowdfunding community connecting nonprofits, donors, and companies in nearly every country. For donors, GlobalGiving provides an additional layer of vetting and due diligence for each of its nonprofit partners every two years, which may include site visit verification. Learn more about GlobalGiving.


GlobalGiving Data is unavailable

We display the GlobalGiving ratings on particular programs of nonprofit organizations. Click here for more information about GlobalGiving ratings.

Note: Encompass Rating Beta V1 does not incorporate impact data into a charity's rating.


Classy


Classy created the Annual Classy Awards to recognize the innovative work of nonprofits around the world. Since 2009, thousands of organizations have been recognized through the Classy Awards. Nominees complete a data-driven framework that helps them to understand and articulate the impact of their programs.


...   Leadership & Adaptability


Charity Navigator will provide an assessment of the organization’s leadership capacity, strategic planning, and the ability to readily innovate or respond to changes in constituent demand/need or other relevant social and economic conditions to achieve the organization’s mission.


Back to Top

...   Culture & Community


Charity Navigator will provide an assessment of the organization’s people operations, connectedness and engagement with the constituents and communities served, and Diversity, Equity and Inclusion measures.


Back to Top